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Negative symptoms occur in several major mental health disorders with undetermined
mechanisms and unsatisfactory treatments; identification of their neural correlates might
unveil the underlying pathophysiological basis and pinpoint the therapeutic targets. In this
study, participants with major depressive disorder (n=24), schizophrenia (n=22), and
healthy controls (n=20) were assessed with 10 frequently used negative symptom scales
followed by principal component analysis (PCA) of the scores. A linear model with the promi-
nent components identified by PCA was then regressed on gray and white-matter volumes
estimated fromT1-weighted magnetic resonance imaging. In depressed patients, negative
symptoms such as blunted affect, alogia, withdrawal, and cognitive impairment, assessed
mostly via clinician-rated scales were inversely associated with gray matter volume in the
bilateral cerebellum. In patients with schizophrenia, anhedonia, and avolition evaluated via
self-rated scales inversely related to white-matter volume in the left anterior limb of internal
capsule/anterior thalamic radiation and positively in the left superior longitudinal fasiculus.
The pathophysiological mechanisms underlying negative symptoms might differ between
depression and schizophrenia. These results also point to future negative symptom scale
development primarily focused on detecting and monitoring the corresponding changes to
brain structure or function.
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INTRODUCTION
Negative symptoms are prevalent, presenting in more than 50%
of psychotic patients (1). Based on the analysis of the National
Institute of Mental Health, Clinical Antipsychotic Trials of Inter-
vention Effectiveness (CATIE) schizophrenia trial, negative symp-
toms have greater impact on functioning than positive or any other
symptoms (2). Moreover, they have undetermined etiology and are
resistant to treatment (3) with existing psychotropic drugs. Despite
initially being thought to be restricted to schizophrenia, negative
symptoms are also present in other major psychiatric disorders,
notably major depressive disorder (4) with possibly different clini-
cal presentations. For instance,anhedonia,one of the core domains
within negative symptoms (5) appears to covary with clinical state
in depressed patients but instead reflects an enduring trait in
schizophrenia (6). Clinical differences such as these may imply
distinct pathophysiology of negative symptoms in depression and
schizophrenia, though as yet this remains uncertain.
Understanding more about the neuroanatomical correlates of
negative symptoms in depression and schizophrenia may help
elucidate whether negative symptoms in the two conditions rep-
resent the same phenomena or not. Although a number of studies
have been conducted examining neural correlates of negative
symptoms, the results have not been consistent and a variety of
regions have been implicated, which prevented us from formulat-
ing an a priori hypothesis. In young women at high risk of depres-
sion, fractional anisotropy (FA) of bilateral cingulum bundles and
left subgenual cingulum are negatively correlated with anhedonia
(7). In depressed adolescents, FA was also found to be negatively
correlated with anhedonia in anterior limb of internal capsule,
posterior cingulum, and inferior-fronto-occipital fasciculus (8). In
schizophrenia, negative symptoms inversely correlated with gray
matter volume in cerebellum (9), left precuneus (10), right poste-
rior cingulate (10); white-matter volume in regions near bilateral
anterior cingulate and right internal capsule (11); FA in internal
capsule (12), anterior thalamic radiation (12), parietal portion of
the superior longitudinal fasciculus (12), fronto-occipital fasci-
culus (12), corpus callosum (12–14), medial frontal gyrus (15),
and inferior frontal white matter (16). Positive correlation with
negative symptoms in schizophrenia was also found in gray mat-
ter volume of right thalamus (17) and FA of an area near right
insula (18), left cingulum and left superior longitudinal fascicu-
lus II (19). However, some researchers have failed to identify any
significant correlation between brain structure and negative symp-
toms (20, 21). Part of the reason for the heterogeneity of results
may result from the heterogeneity in ways in which negative symp-
toms were measured. Many psychological scales have been devised
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for the evaluation of negative symptoms. In spite of the appreciable
quantity of scales, individually, none covers all aspects of negative
symptoms and none has been demonstrated to be superior in
terms of severity evaluation or prognostic prediction.
In order to avoid selection bias, we decided to assess negative
symptoms by using a large number of negative symptom scales,
then employing a data reduction approach with PCA to iden-
tify the major dimensions of negative symptoms and specify their
magnetic resonance imaging (MRI) anatomical correlates; namely
gray and white-matter volumes estimated with voxel-based mor-
phometry (VBM) (22). To our knowledge, this is the first study
exploring negative symptoms in schizophrenia and major depres-
sive disorder using integrative information from a large number
of negative symptom scales. We hypothesize that distinct patterns
of neural correlates will be associated with different domains of
negative symptoms in depression and schizophrenia, respectively.
MATERIALS AND METHODS
PARTICIPANTS AND RECRUITMENT
Twenty-two participants with DSM-IV schizophrenia, 24 patients
with DSM-IV major depressive disorder, and 20 control partici-
pants, were recruited to take part in the study (Table 1). Inclusion
criteria were: adequate English proficiency and age between 18 and
65 years. Exclusion criteria were: brain structural abnormality, his-
tory of major medical or neurological disorder, substance depen-
dence, and any contraindications to MRI scanning contraindi-
cations. First-degree family history of schizophrenia or bipolar
disorder was an additional exclusion criterion for depressed and
control subjects. The study was approved by the Cambridgeshire
3 National Health Service research ethics committee with written
informed consent obtained from every participant.
Thirteen depressed participants were taking antidepressants
with the following daily dose ranges: citalopram 30–60 mg, mir-
tazapine 30–45 mg, venlafaxine 75–225 mg. Nearly, all patients
with schizophrenia were on atypical antipsychotic medication and
the mean chlorpromazine equivalent dose was 401.243 (standard
deviation 91.43) mg/day. Three depressed patients were taking
antipsychotics: risperidone 2 mg, quetiapine 100 mg, and queti-
apine 100 mg. Eight schizophrenia patients were also taking anti-
depressant medication: citalopram 20–40 mg, fluoxetine 20 mg,
mirtazapine 45 mg, and venlafaxine 150–225 mg.
NEGATIVE SYMPTOM SCALES
Ten commonly used negative symptom scales were administered:
the negative subscale of the Positive and Negative Syndrome Scale
(PANSS) (23); the Snaith–Hamilton Pleasure Scale (SHAPS) (24);
Chapman Physical Anhedonia Scale (25); Chapman Social Anhe-
donia Scale (25); anhedonia subscale of Beck Depression Inventory
(BDI) (26); negative symptom subscale of Brief Psychiatric Rating
Scale (BPRS) (27); Motivation and Energy Inventory (MEI) social
subscale (28); MEI physical subscale (28); Temporal Experience of
Pleasure Scale (TEPS) anticipatory subscale (29); and TEPS con-
summatory subscale (29). Though the PANSS is generally applied
to psychotic patients, the PANSS negative subscale has been shown
to be a valid instrument in patients with major depressive disorder
(30). The BPRS negative symptom scale includes items such as
blunted affect, emotional withdrawal, and motor retardation. All
scales were self-reported, except the PANSS and BPRS. Higher
scores denote more severe negative symptoms, except on the MEI
and TEPS. In order to avoid selection bias, we tried to cover all
dimensions of negative symptoms: PANSS and BPRS negative
symptom subscales are related to impaired cognition, withdrawal,
blunted affect, and alogia while the remainder is associated to a
greater extent with anhedonia and avolition. It has been suggested
that patients with certain mental disorders only suffer a specific
type instead of global anhedonia, for instance, anticipatory anhe-
donia in schizophrenia (29). Many scales have been created for
subdivisions of anhedonia, such as the Chapman and TEPS scales
used in this study.
MRI IMAGES ACQUISITION AND VBM PRE-PROCESSING
Brain MRI T1-weighted images were acquired by a Siemens
Tim Trio operating at 3 T (Wolfson Brain Imaging Centre,
University of Cambridge) with the following parameters: slice
thickness= 1 mm, repetition time= 2000 ms; echo time= 30 ms;
flip angle= 78°; in-plane resolution 2 mm× 2mm; matrix size
240× 256; bandwidth 2232 Hz/pixel.
Magnetic resonance imaging datasets were pre-processed with
VBM8 in Statistical Parametric Mapping (SPM8)1 in MATLAB
(Math-Works, Natick, MA, USA) following the instructions in
the online manual2. To begin with, images were segmented into
gray and white matter then Diffeomorphic Anatomical Registra-
tion through Exponentiated Lie Algebra (DARTEL) was used to
increase the accuracy of inter-subject alignment by modeling the
shape of each brain using three parameters for each voxel (31).
Following DARTEL, templates were generated and registered to
the Montreal Neurological Institute (MNI) space by affine trans-
formation. Afterward, all images were non-linearly warped onto
the templates and smoothed with 10 mm full width at half maxi-
mum Gaussian kernel as suggested in the manual. Possible spatial
expansion or contraction during the normalization process was
modulated by the Jacobian determinant to preserve the original
tissue volumes.
PRINCIPAL COMPONENT ANALYSIS AND NEUROIMAGING STATISTICS
Principal component analysis simplifies, summarizes, and inte-
grates data along with a reduction in statistical comparisons, thus
avoiding inflation of type1 errors. PCA with direct oblimin rota-
tion (32) was performed on all negative symptom scales in all par-
ticipants via Statistical Package for Social Sciences software (SPSS
version 21). Rotation was applied to improve the ease of interpre-
tation, and oblique instead of orthogonal rotation was used due
to the presumed association between components. Components
with eigenvalues >1 were identified. Participants’ loading scores
of these major components were then used for subsequent MRI
image analyses in FMRIB Software Library (FSL) version 5.03. A
general linear model (GLM) regressed loading scores of the major
1http://www.fil.ion.ucl.ac.uk/spm
2http://www.fil.ion.ucl.ac.uk/~john/misc/VBMclass10.pdf
3http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/
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Table 1 | Demographics and participants’ characteristics.
Control Depression Depression vs. Schizophrenia Schizophrenia vs.
(±SD) (±SD) control (t value/d.f.) (±SD) control (t value/d.f.)
p value p value
Number of subjects 20 24 – 22 –
Gender
(women/men)
4/16 7/17 −0.69/42
0.50
3/19 0.54/40
0.59
Age (years) 34.30±10.37
(range: 19–49)
33.08±9.15
(range: 19–54)
0.41/42
0.68
32.73±7.62 (range:
21–46)
0.56/40
0.576
Estimated IQ 115.35±19.79
(range: 87–158)
107.08±16.60
(range: 87–139)
1.51/42
0.14
99.38±19.16
(range: 83–151)
2.63/39
0.01
Education (years) 14.79±1.96
(range: 11–19)
13.43±2.21
(range: 11–17)
2.08/40
0.04
13.62±2.11
(range: 11–17)
1.81/38
0.08
Maternal education
(years)
13.60±2.77
(range: 9–19)
13.00±1.65
(range: 11–16)
0.70/23.33
0.49
12.80±2.83 (range:
9–19)
0.78/28
0.44
Handness 16 right 3 left
1 missing data
22 right 2 left – 16 right 5 left
1 missing data
–
Ethnicity 16 white-British
1 Asian-Indian
1 other ethnicity
2 missing data
20 white-British
3 white-others
1 Asian-Indian
– 17 white-British
1 white-Irish
1 white-others
1 Asian-Indian
2 missing data
–
Current employment 13 working (paid)
3 unemployed
1 student
3 missing data
13 working (paid)
4 unemployed
2 student
2 others
3 missing data
– 4 working (paid)
3 voluntary
10 unemployed
1 other
4 missing data
–
Alcohol 1 none
5 <weekly
12 1–3 times/week
1 almost daily
1 missing data
5 none
1 1–2 times
8 <weekly
6 1–3 times/week
4 almost daily
– 2 none
1 1–2 times
3 <weekly
9 1–3 times/week
4 almost daily
3 missing data
–
Smoking 9 none
2 1–2 times
1 <weekly
7 almost daily
1 missing data
7 none
1 1–2 times
3 <weekly
13 almost daily
– 3 none
18 almost daily
1 missing data
–
Cannabis 7 none
3 1–3 times
7 <weekly
1 1–3 times/week
1 almost daily
1 missing data
11 none
4 1–2 times
5 <weekly
2 1–3 times/week
2 almost daily
– 4 none
2 1–3 times
4 <weekly
3 1–3 times/week
7 almost daily
2 missing data
–
HAMD-17 score (50) 0.65±0.99
(range: 0–3)
16.33±5.37
(range: 8–27)
−14.03/42
<0.000001
9.45±5.54
(range: 2–20)
−7.33/40
<0.000001
(Continued)
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Table 1 | Continued
Control Depression Depression vs. Schizophrenia Schizophrenia vs.
(±SD) (±SD) control (t value/d.f.) (±SD) control (t value/d.f.)
p value p value
PANSS total score 31.05±2.37
(range: 30–39)
55.08±14.60
(range: 35–98)
−7.94/42
<0.000001
58.14±17.81
(range: 34–101)
−7.06/40
<0.000001
PANSS negative
score
7.15±0.37
(range: 7–8)
13.50±6.19
(range: 7–33)
−5.02/42
0.000044
16.05±5.41
(range: 9–31)
−7.69/40
<0.000001
SHAPS score 23.30±3.66
(range: 15–29)
33.42±6.81
(range: 15–41)
−6.27/42
<0.000001
28.86±6.25
(range: 14–38)
−3.47/40
0.001
Chapman physical
score
12.55±9.07
(range: 2–34)
29.54±14.11
(range: 4–51)
−4.83/42
0.000021
23.00±9.45
(range: 4–35)
−3.65/40
0.001
Chapman social
score
12.20±7.02
(range: 3–32)
22.79±10.94
(range: 3–39)
−3.88/42
0.000382
15.55±7.55
(range: 6–32)
−1.48/40
0.146
MEI social score 28.90±9.77
(range: 6–45)
16.17±9.31
(range: 3–41)
4.42/42
0.000069
18.95±6.08
(range: 1–26)
4.00/40
0.000264
MEI physical score 25.10±7.50
(range: 11–39)
11.25±6.11
(range: 3–25)
6.75/42
<0.000001
15.73±6.24
(range: 0–25)
4.42/40
0.000075
TEPS anticipatory
score
42.80±8.43
(range: 20–55)
28.71±8.44
(range: 11–53)
5.52/42
0.000002
35.36±9.23
(range: 17–55)
2.72/40
0.01
TEPS consummatory
score
37.15±7.09
(range: 19–48)
26.58±9.55
(range: 10–45)
4.09/42
0.000189
29.73±7.09
(range: 21–48)
3.39/40
0.002
BDI anhedonia score 1.10±1.37
(range: 0–4)
5.96±2.26
(range: 2–11)
−8.41/42
<0.000001
4.91±2.56
(range: 0–11)
−5.92/40
0.000001
BPRS negative
symptom subscore
3 6.08±3.27
(range: 3–17)
−4.62/42
0.00012
7.14±2.64
(range: 3–14)
−7.34/40
<0.000001
Cognition/expression
component
−0.87±0.12
(range: −1.17 to −0.74)
0.17±1.06
(range: −1.05–3.54)
−4.77/42
0.000077
0.61±0.84
(range: −0.71–2.90)
−8.14/40
<0.000001
Pleasure/motivation
component
−0.95±0.64
(range: −2.06–0.25)
0.73±0.84
(range: −1.44–1.93)
−7.38/42
<0.000001
0.07±0.68
(range: −1.56–1.39)
−4.99/40
0.000012
components onto gray (or white) matter volumes at each intra-
cerebral voxel with nuisance covariates of age, gender, and total
gray (or white) matter volumes. Four models were regressed for
every loading score: gray matter in depressed group; gray matter in
schizophrenia group; white matter in depressed group; and white
matter in schizophrenia group. In each analysis, a significance
level of P ≤ 0.05 family-wise error corrected for multiple com-
parisons was applied using threshold-free cluster enhancement
(TFCE) (33). Regions significantly correlated with loading scores
were localized by the Harvard–Oxford Cortical Structural Atlas,
Johns Hopkins University White-Matter Tractography Atlas, and
Cerebellar Atlas in MNI152 space4. If two or more regions were sig-
nificantly related to the component scale in the same patient group
and the same tissue type, then inter-regional correlation between
the extracted volumes of these areas would also be calculated in
the patient and control groups.
4http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases
BETWEEN-GROUP STRUCTURAL DIFFERENCES RELATED TO NEGATIVE
SYMPTOMS
After controlling for age, gender, and total gray (or white) matter
volumes, regions displaying a significant relationship with princi-
pal components in patient groups were used as masks to extract tis-
sue volumes from both the patient and control groups. Using SPSS,
between-group differences were assessed via independent, two-
sample T -tests on these extracted volumes to evaluate the extent
of structural group differences related to negative symptoms.
RESULTS
PRINCIPAL COMPONENT ANALYSIS OF NEGATIVE SYMPTOM SCALES
With a Kaiser–Meyer–Olkin test-statistic value of 0.793 and
Bartlett’s test of sphericity with p< 0.000001, PCA was ade-
quately completed. Two major components were yielded with
eigenvalues >1 (Supplementary Material) collectively explain-
ing 69.93% of the total variance. PANSS negative and BPRS
negative subscales loaded more than 0.9 in the pattern matrix
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onto one component, which was primarily related to impaired
cognition, withdrawal, blunted affect, and alogia. The other
eight scales loaded onto a second component associated pri-
marily with anhedonia and avolition. We thus identified two
principal components, one coding for “cognition/expression”
and another coding for “pleasure/motivation” (Tables 1 and
2). Both illness groups expressed each component significantly
more than controls (Figure 1). The depressed group scored
highest (most impaired) in the “pleasure/motivation” compo-
nent (t= 2.382, p= 0.026) whereas the schizophrenia scored
highest in the “cognition/expression” component (t= 2.627,
p= 0.016).
BRAIN STRUCTURAL CORRELATES OF NEGATIVE SYMPTOMS
In the schizophrenia patient group, the principal component
coding for “pleasure/motivation” was found to be inversely cor-
related with white-matter volume in the left anterior limb of
internal capsule/anterior thalamic radiation and positively cor-
related with left superior longitudinal fasiculus (Figure 2). Since
the principal component coding for “pleasure/motivation” in the
schizophrenia group was not significantly correlated with the
HAMD-17 score with Pearson correlation coefficient r=−0.08
and p= 0.741, the assumption of secondary negative symptoms
due to depression is not favored. The principal component coding
for “cognition/expression” was significantly inversely correlated
with bilateral cerebellar gray matter in the depression patient
group (Figure 2). These associations were significantly different
between groups (Table 3).
The correlation between white-matter volume in the left ante-
rior limb of internal capsule/anterior thalamic radiation and
left superior longitudinal fasciculus in the schizophrenia group
was high with a Pearson correlation coefficient r=−0.66 and
p< 0.001 (Figure 3) but non-significant in the control group
with r= 0.093 and p= 0.696. After Fisher’s r to z transformation,
the group difference of the correlations was significant (Z = 2.65,
p< 0.01). No regions in the gray matter of schizophrenia group
or white matter of depression group were significantly correlated
with these components.
Table 2 | Pattern matrix of principal component analysis for the 10
negative symptom scales.
Negative symptom scale Pleasure/
motivation
component
Cognition/
expression
component
Chapman social scale 0.85 −0.22
Chapman physical scale 0.86 −0.06
SHAPS scale 0.73 0.13
MEI social scale −0.82 −0.04
MEI physical scale −0.75 0.02
TEPS anticipatory scale −0.79 −0.08
TEPS consummatory scale −0.73 −0.18
BDI anhedonia scale 0.70 0.18
PANSS negative subscale 0.04 0.95
BPRS negative subscale 0.05 0.93
BETWEEN-GROUP STRUCTURAL DIFFERENCES RELATED TO NEGATIVE
SYMPTOMS
At a significance level of P ≤ 0.05, group differences between
controls and patients were revealed in extracted volumes from
only one region identified as having a significant relationship
to negative symptom scores: the anterior limb of the internal
capsule/anterior thalamic radiation (Table 4).
DISCUSSION
NEGATIVE SYMPTOMS: TWO COMPONENTS, TWO DISORDERS, AND
TWO TISSUE TYPES
Neuroanalysis following PCA identified neural signatures of two
distinct dimensions of negative symptoms in schizophrenia and
FIGURE 1 | Boxplots of scores in cognition/expression component and
pleasure/motivation component are shown. Both patient groups are
significantly different from the control group in these two components
(Table 1).
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FIGURE 2 | Continued
FIGURE 2 | Continued
Neural signatures of negative symptoms in schizophrenia and
depression groups are shown. Significant association of white-matter
volumes with the principal component coding for “pleasure/motivation”
was found in the schizophrenia group: (A) left superior longitudinal fasiculus
(SLF) with cluster size=105 voxels and peak p=0.017. (B) Left anterior limb
of internal capsule/anterior thalamic radiation with cluster size=114 voxels
and peak p=0.014. (C) Significant association of gray matter volumes with
the principal component coding for “cognition/expression” was found in
the depressed group: cerebellum with a cluster of size=2212 voxels and
peak p=0.002. Peak voxels shown with corresponding Montreal
Neurological Institute (MNI) coordinates. Scatter plots: controlling for age,
gender, total gray or white-matter volume, partial correlation coefficients (r )
between the extracted volumes and principal component scores are
calculated within group and are shown here [(A): r = 0.85, (B) r =−0.84,
(C) r =−0.79]. Please note that the partial correlation coefficients are
expected to be high as the regions in which we quantify that these
correlations were defined as being regions with significant associations
between volume and principal component expression.
depression, respectively; that is, a principal component coding for
“cognition/expression” in gray matter in depression and a princi-
pal component coding for “pleasure/motivation” in white matter
in schizophrenia. Therefore, as opposed to a common underlying
process proposed by Foussias et al. (34), fundamental discrep-
ancies in the brain structural basis of negative symptoms may
exist between different diagnoses and distinct domains. Recruiting
nearly 500 participants, a recent study has attempted to develop
a new negative symptom assessment for schizophrenia (CAINS:
Clinical Assessment Interview for Negative Symptoms). Interest-
ingly, structural analysis of all the items in the CAINS revealed
two major elements of negative symptoms similar to our findings,
termed by the CAINS researchers as “expression,” a measure of
behavioral, social, and emotional expression, and “motivation and
pleasure” (3).
Both component scores of depression and schizophrenia
patients differ significantly from the controls (Table 1, Figure 1).
However, patients showed significant neural correlations with the
component, which they did not clinically express predominantly.
For instance, the schizophrenia group scored higher in the “cog-
nition/expression” component, with which they failed to demon-
strate neural correlates. Further, despite prominent differences in
clinical negative symptom severity (Table 1), controls and patients
did not differ significantly in all of the extracted volumes within
the neural signatures (Table 4). Thus, brain regions in which there
are inter-individual differences that relate to symptom severity do
not necessarily show differences between groups in average brain
volume. This suggests that there may be some neural deficits that
contribute to the category of developing either disorder or some
separate deficits that influence how severely the illness is expressed.
THE CEREBELLUM IN DEPRESSION
Although initially considered as a motor coordinator, the cere-
bellum is now known to play a role in emotional regulation and
cognition, supported by its widespread connections to the lim-
bic system, the frontal, parietal, prefrontal, occipital, and temporal
cortex. The cerebellum is activated in a variety of mental activities,
including facial recognition, emotion attribution, theory of mind
attributions, directed attention, memory, and empathy (35, 36)
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Table 3 | Group differences in the correlation of the brain regions shown in Figure 2 with the negative symptoms of first two principal
components.
Scale Region Group Fisher r to Z significance test
r v.s. Group Z pValue
Cognition/ Cerebellum Control −0.25 Depression 2.51 0.012
Expression
component
Depression −0.79 – – –
Schizophrenia −0.09 Depression 3.10 0.002
Pleasure/motivation
component
Left superior longitudinal
fasciculus
Control 0.10 Schizophrenia −3.45 0.0006
Depression −0.05 Schizophrenia −4.13 0.00002
Schizophrenia 0.85 – – –
Left anterior limb of internal
capsule/anterior thalamic
radiation
Control 0.25 Schizophrenia 4.45 0.000009
Depression −0.47 Schizophrenia 2.27 0.0232
Schizophrenia −0.84 – – –
Controlling for age, gender, and total gray or white-matter volume, partial correlation coefficients (r) between the extracted volumes and principal component scores
are calculated within group and later transformed to Z scores. Z scores and p-values represent the degree to which the correlations differ between groups.
FIGURE 3 | Inter-regional correlation in schizophrenia group. Linear
regression was performed with a dependent variable of extracted volumes
in the left superior longitudinal fasiculus or left anterior limb of internal
capsule/anterior thalamic radiation and covariates of age, gender, and total
white-matter volumes. Pearson correlation coefficient between the
residuals of extracted volumes from these two regions is r =−0.66 with
p<0.001 in the schizophrenia group.
and has been referred to as the “emotional pacemaker” (37). Func-
tional mapping of the cerebellum has been established based on
functional MRI studies and clinical lesion reports. The posterior
lobules VI, VII, and Crus were found to be linked to cognition,
the posterior vermis to be associated with emotion and lobules
I–V related to sensorimotor function (37). Indeed, the cerebellar
cognitive affective syndrome following posterior cerebellar lobe
lesion includes negative symptoms such as passivity, blunted affect,
and withdrawal (37). Also, early in 1992, Dolan et al. reported
increased regional cerebral blood flow of the cerebellar vermis in
depressed patients with cognitive disturbance (38). Furthermore,
in an fMRI meta-analysis, the cerebellum has been identified as an
important area of dysfunction in depression (39). In our depressed
group, the bilateral lobules I–IV, V, VI, Crus, and vermis were
found to be negatively correlated with the principal component
coding for “cognition/expression” corresponding to the functional
topography.
WHITE MATTER IN SCHIZOPHRENIA
Compared to control participants and based on post-mortem
and positron emission tomography studies, patients with schiz-
ophrenia are suspected to have higher metabolic rates in the
superior longitudinal fasciculus and anterior limb of the inter-
nal capsule (40, 41) suggesting roles in the pathophysiology of
the disorder. The anterior limb of the internal capsule serves as
a bridge between the thalamus, cingulate, and prefrontal cortices
and thus plays an important role in motivation, reward, and emo-
tion (8). We identified neural correlates of negative symptoms
in the superior longitudinal fasciculus III, which connects the
supramarginal gyrus with ventral premotor and prefrontal areas
(42). The supramarginal gyrus has been reported to participate
in execution and mental simulation of action (43). Furthermore,
associations between negative symptoms and these two areas have
been reported in terms of FA (12) and now white-matter volume in
this study. Taken together, this evidence justifies the association of
anterior limb of the internal capsule and superior longitudinal fas-
ciculus with a pleasure/motivation domain of negative symptoms.
In the schizophrenia group, we demonstrated a significant correla-
tion between extracted volumes in these two regions (r =−0.66)
(Figure 3), which was non-significant in the controls. Certainly,
schizophrenia has been regarded as a disease of disconnectivity
(44) and this evidence strengthens that assertion.
NEGATIVE SYMPTOM SCALE DEVELOPMENT
Encouraged by the National Institute of Mental Health Consen-
sus Development Conference on Negative Symptoms in Rockville,
MD, USA, 2005 (45), several attempts have been made in recent
years by developing a new negative symptom scale. However, the
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Table 4 | Differences between patients and controls in the extracted volumes of areas with significant relationships to the negative symptoms
principal components, controlling with age, gender, and total gray or white-matter volume.
Scale Area Compared groups
(mean volume)
t Value pValue Degree of
freedom
Cognition/expression component Cerebellum Control (10179.77) −0.83 0.409 42
Depressed (10226.42)
Pleasure/motivation component Left superior longitudinal fasciculus Control (539.19) 1.15 0.257 40
Schizophrenia (508.06)
Left anterior limb of internal
capsule/anterior thalamic radiation
Control (412.33) −2.29 0.027 40
Schizophrenia (420.73)
absence of scales emphasizing the correspondence between scores
and structural, or indeed functional, brain changes associated with
mental disorders might be accounted for by the diverse findings in
the neural correlates of negative symptoms provided here. Despite
being difficult to develop, scales reflecting alterations in brain
structure and function could be clinically valuable enabling prog-
nosis prediction, disease progress monitoring, and the probing of
etiological mechanisms.
Current scales tend to mix several domains of negative symp-
toms. Nevertheless as shown in our study, it is likely that instead of
the whole spectrum, only specific components of negative symp-
toms correspond to alterations of brain structures. According
to our findings, anhedonia and avolition were linked to brain
alteration in schizophrenia whereas blunted affect, alogia, with-
drawal, and cognitive dysfunction were associated with depression.
However, we were unable to distinguish neural correlates of dif-
ferent anhedonia types. Future studies may delve deeper into this
topic.
Several limitations should be considered when interpreting our
result. We included more participants than some published stud-
ies (9, 11, 16, 17), but sample size was still small-to-moderate.
Besides, the information regarding disease duration was absent.
Furthermore, although we tried to cover all dimensions of negative
symptoms by including a large number of frequently used scales,
our list of assessments was by no means exhaustive. Other negative
symptom scales could be added in future studies. Additionally, the
positive correlation in the left superior longitudinal fasciculus with
negative symptoms in the schizophrenia group might indicate a
compensatory mechanism in response to the deficit. However, we
were prevented from providing any cellular explanation of results
due to the nature of MRI image analysis. Atypical antipsychotics
and cannabis have been associated with brain structural change
(46, 47) and were widely used in our patients. Based on two sys-
tematic reviews, antipsychotics may alter gray matter volume (48,
49). However, there has been no consensus regarding the direction-
ality of the effect (i.e., increasing or decreasing). Furthermore, we
did not find any significant structural difference between patients
and controls in the regions in which inter-individual variability
of symptoms within patients was associated with inter-individual
variability in brain structure. Consequently, we are prevented from
determining the exact medication effects. Drug-naïve patients
should be recruited in future studies.
In conclusion, in correspondence with the large CAINS study,
we identified two major domains of negative symptoms. Neural
signatures of these domains were found in depression and schiz-
ophrenia. Future research may investigate the association of these
regions with negative symptoms. New scales linking negative
symptoms with structural brain change are anticipated.
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